Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Dermatologic 1

Conditions

Melanoma 5Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 22Nivolumab 17Magnetic Resonance Spectroscopy 12Specimen Handling 10Cyclophosphamide 9Radiosurgery 7Drug Therapy 6Radiotherapy 5Paclitaxel 5Ipilimumab 5fludarabine 4Biopsy 4trametinib 3sargramostim 3Trastuzumab 3Taxes 3Pemetrexed 3Metformin 3Interleukin-2 3Immunoglobulin G 3Gemcitabine 3Carboplatin 3Bevacizumab 3tremelimumab 2temsirolimus 2poly ICLC 2pertuzumab 2osimertinib 2motexafin gadolinium 2epacadostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × naporafenib × Dermatologic × Clear all
NCT02974725 2025-04-13

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Novartis

Phase 1 Terminated
241 enrolled
DermatologicThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡